Live Breaking News & Updates on Aravive

Stay informed with the latest breaking news from Aravive on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Aravive and stay connected to the pulse of your community

Aravive (NASDAQ:ARAV) Trading 6.4% Higher

Aravive, Inc. (NASDAQ:ARAV – Get Free Report)’s share price traded up 6.4% during mid-day trading on Thursday . The stock traded as high as $0.13 and last traded at $0.13. 1,011,418 shares traded hands during mid-day trading, a decline of 71% from the average session volume of 3,496,876 shares. The stock had previously closed at […]

United-states , Nasdaq , Citigroup-inc , Aravive-inc , Millennium-management , Geode-capital-management , Aravive-company-profile , Get-free-report , Capital-management , Street-group , Aravive-daily

Aravive, Inc. (NASDAQ:ARAV) Short Interest Up 62.9% in September

Aravive, Inc. (NASDAQ:ARAV – Get Free Report) was the target of a significant increase in short interest in September. As of September 15th, there was short interest totalling 7,300,000 shares, an increase of 62.9% from the August 31st total of 4,480,000 shares. Based on an average daily volume of 6,950,000 shares, the days-to-cover ratio is […]

United-states , William-blair , Cantor-fitzgerald , Virtu-financial , Freedom-wealth-alliance , Citigroup-inc , Nasdaq , Aravive-inc , Charles-schwab-investment-management-inc , Aravive-company-profile , Get-free-report , Wealth-alliance

Aravive (NASDAQ:ARAV) Cut to "Neutral" at Cantor Fitzgerald

Cantor Fitzgerald downgraded shares of Aravive (NASDAQ:ARAV – Free Report) from an overweight rating to a neutral rating in a research report released on Tuesday morning, Marketbeat.com reports. Cantor Fitzgerald also issued estimates for Aravive’s FY2023 earnings at ($0.52) EPS and FY2024 earnings at ($0.08) EPS. Other analysts have also recently issued reports about the […]

United-states , William-blair , Cantor-fitzgerald , Artal-group , Geode-capital-management , Aravive-inc , Citigroup-inc , Renaissance-technologies , Millennium-management , Free-report , Capital-management , Get-free-report

Aravive, Inc. (NASDAQ:ARAV) Short Interest Up 12.9% in July

Aravive, Inc. (NASDAQ:ARAV – Get Free Report) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 7,610,000 shares, an increase of 12.9% from the July 15th total of 6,740,000 shares. Based on an average trading volume of 1,960,000 shares, the […]

United-states , William-blair , Cantor-fitzgerald , Charles-schwab-investment-management-inc , Nasdaq , Freedom-wealth-alliance , Virtu-financial , Citigroup-inc , Aravive-company-profile , Aravive-inc , Get-free-report , Wealth-alliance

Aravive (NASDAQ:ARAV) Rating Lowered to Neutral at HC Wainwright

HC Wainwright downgraded shares of Aravive (NASDAQ:ARAV – Free Report) from a buy rating to a neutral rating in a research note published on Thursday, MarketBeat reports. Several other analysts have also recently commented on ARAV. BTIG Research cut shares of Aravive from a buy rating to a neutral rating in a research note on […]

United-states , Citigroup-inc , Cantor-fitzgerald , Millennium-management , Geode-capital-management , Artal-group , Aravive-company-profile , Renaissance-technologies , Aravive-inc , Free-report , Moderate-buy

Aravive (NASDAQ:ARAV) Lowered to "Neutral" at HC Wainwright

HC Wainwright cut shares of Aravive (NASDAQ:ARAV – Free Report) from a buy rating to a neutral rating in a report released on Thursday morning, MarketBeat.com reports. A number of other equities analysts have also recently issued reports on ARAV. Cantor Fitzgerald reaffirmed an overweight rating and issued a $18.00 target price on shares of […]

United-states , Cantor-fitzgerald , Freedom-wealth-alliance , Virtu-financial , Aravive-inc , Aravive-company-profile , Geode-capital-management , Free-report , Moderate-buy , Get-free-report , Capital-management

William Blair Downgrades Aravive (NASDAQ:ARAV) to Market Perform

William Blair cut shares of Aravive (NASDAQ:ARAV – Free Report) from an outperform rating to a market perform rating in a research report report published on Thursday, Marketbeat.com reports. A number of other equities research analysts also recently weighed in on the stock. HC Wainwright downgraded shares of Aravive from a buy rating to a […]

United-states , William-blair , Freedom-wealth-alliance , Aravive-inc , Citigroup-inc , Charles-schwab-investment-management-inc , Cantor-fitzgerald , Aravive-company-profile , Virtu-financial , Free-report , Moderate-buy , Get-free-report

Aravive, Inc. : ARAV Stock Price | US03890D1081

Aravive, Inc. (ARAV.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Aravive, Inc. | Nasdaq: ARAV | Nasdaq

United-states , Aravive-inc , Drug-administration , European-commission , Fast-track-designation , United-states-food , Orphan-drug-designation , Aravive , Nc-quotes , Tock-quote , Tock

Aravive To Participate in the Jefferies Global Healthcare Conference

HOUSTON, June 05, 2023 -- Aravive, Inc. , a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D., DABT,... | June 5, 2023

Texas , United-states , New-york , Houston , Gail-mcintyre , Rudy-howard , Corey-davis , Nasdaq , Cancer-prevention-research-institute-of-texas , Lifesci-advisors , Aravive-inc , Globenewswire-inc

ARAVIVE, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

Item 7.01. Regulation FD Disclosure.

On May 25, 2022, Aravive, Inc. issued a press release announcing
the presentation of updated results from its ongoing Phase 2 trial of
batiraxcept in clear cell... | May 25, 2023

United-states , Chicago , Illinois , American , Nivolumab-nivo , Cabozantinib-cabo , Exchange-commission , Securities-exchange , American-society-of-clinical-oncology , Aravive-inc , Clinical-oncology , Current-report